Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
AVRO Stock Summary
Top 10 Correlated ETFs
AVRO
In the News

Avrobio: Net-Net Biotech Pursuing Strategic Alternatives
After monetizing one of its pipeline candidates, Avrobio has cash well in excess of its market cap. The company announced its search for strategic alternatives recently. The process could close its valuation gap soon. There is potential for significantly more value if Avrobio can also monetize its remaining candidates.

AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%
AVROBIO (AVRO) announces its decision to halt all development programs in its quest to explore strategic alternatives. The stock of the company surges 46% in response on Wednesday.

How to Handle Penny Stocks Volatility in 2023
Penny stocks continue to offer incredible opportunities for investors in 2023. As high-growth, micro-cap equities, they have the potential to outperform traditional stocks, particularly given their inherent affordability, which allows for a broader, more diversified portfolio.

Why Is AVROBIO (AVRO) Stock Up 83% Today?
AVROBIO (NASDAQ: AVRO ) stock is seeing massive gains on Monday as the company sells one of its gene therapies to Novartis (NYSE: NVS ). This deal has Novartis agreeing to pay $87.5 million in cash to AVROBIO for an investigational hematopoietic stem cell ( HSC ) gene therapy program.

AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study
Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different tissues.

AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study
AVROBIO Inc (NASDAQ: AVRO) reported new interim data from the Phase 1/2 gene therapy trial of AVR-RD-04 for cystinosis. Cystinosis is a condition characterized by the accumulation of the amino acid cystine (a building block of proteins) within cells.

After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data
Avrobio Inc's AVRO gene therapy for a rare lysosomal storage disorder showed potential durability in the first three patients more than one year after infusion. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Trading Penny Stocks? Top Stock Market News for February 9th, 2022
What you need to know about trading penny stocks today The post Trading Penny Stocks? Top Stock Market News for February 9th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 19.7% in 4 Weeks
The heavy selling pressure might have exhausted for AVROBIO, Inc. (AVRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

AVROBIO to Present at Cowen's 2nd Annual Genetic Medicines Summit
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced Azadeh Golipour, Ph.D., chief technology officer at AVROBIO, will present virtually at Cowen's 2nd Annual Genetic Medicines Summit at 2:00 p.m. ET on Thursday, Feb. 3, 2022. About AVROBIO Our vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease throu
AVRO Financial details
AVRO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -3.45 | -2.63 | -3.27 | -2.75 | -2.42 | |
Operating cash flow per share | -2.8 | -2.47 | -2.73 | -2.29 | -2.22 | |
Free cash flow per share | -2.94 | -2.52 | -2.76 | -2.34 | -2.23 | |
Cash per share | 9.4 | 6.82 | 7.17 | 4.42 | 2.12 | |
Book value per share | 9.09 | 6.78 | 7.02 | 3.95 | 1.72 | |
Tangible book value per share | 9.09 | 6.78 | 7.02 | 3.95 | 1.72 | |
Share holders equity per share | 9.09 | 6.78 | 7.02 | 3.95 | 1.72 | |
Interest debt per share | 0 | 0 | 0 | 0.34 | 0.41 | |
Market cap | 223.7M | 552.21M | 504.71M | 164.99M | 31.05M | |
Enterprise value | 97.4M | 365.16M | 245.03M | -9.63M | -44.05M | |
P/E ratio | -4.83 | -7.66 | -4.26 | -1.4 | -0.29 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -5.94 | -8.16 | -5.11 | -1.68 | -0.32 | |
PFCF ratio | -5.67 | -7.97 | -5.05 | -1.64 | -0.32 | |
P/B Ratio | 1.83 | 2.97 | 1.98 | 0.97 | 0.41 | |
PTB ratio | 1.83 | 2.97 | 1.98 | 0.97 | 0.41 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -2.11 | -4.82 | -2.04 | 0.08 | 0.42 | |
EV to operating cash flow | -2.59 | -5.4 | -2.48 | 0.1 | 0.45 | |
EV to free cash flow | -2.47 | -5.27 | -2.45 | 0.1 | 0.45 | |
Earnings yield | -0.21 | -0.13 | -0.23 | -0.71 | -3.41 | |
Free cash flow yield | -0.18 | -0.13 | -0.2 | -0.61 | -3.14 | |
Debt to equity | 0 | 0 | 0 | 0.09 | 0.23 | |
Debt to assets | 0 | 0 | 0 | 0.07 | 0.17 | |
Net debt to EBITDA | 2.73 | 2.47 | 2.16 | 1.47 | 0.71 | |
Current ratio | 12.26 | 13.96 | 16.09 | 10.27 | 8.23 | |
Interest coverage | 0 | 0 | 0 | 530.54 | -352.62 | |
Income quality | 0.81 | 0.93 | 0.83 | 0.82 | 0.92 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.05 | 0.02 | 0.01 | 0.03 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -4.82 | -1.86 | -0.98 | -1.76 | -0.19 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 26.57 | 20.03 | 22.75 | 15.63 | 9.7 | |
ROIC | -0.38 | -0.4 | -0.47 | -0.64 | -1.12 | |
Return on tangible assets | -0.35 | -0.36 | -0.44 | -0.58 | -1.02 | |
Graham Net | 8.59 | 6.31 | 6.72 | 3.64 | 1.46 | |
Working capital | 119.41M | 181.68M | 250.63M | 179.76M | 87.56M | |
Tangible asset value | 122.18M | 186.01M | 254.34M | 169.48M | 75.37M | |
Net current asset value | 118.73M | 181.2M | 250.35M | 164.78M | 71.1M | |
Invested capital | 0 | 0 | 0 | 0.09 | 0.23 | |
Average receivables | 772.5K | 1.84M | 2.35M | 2.63M | 1.48M | |
Average payables | 1.66M | 3.37M | 3.32M | 3.08M | 1.94M | |
Average inventory | -772.5K | -1.84M | -2.35M | -2.63M | -1.48M | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.38 | -0.39 | -0.47 | -0.69 | -1.41 | |
Capex per share | -0.14 | -0.06 | -0.03 | -0.06 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.65 | -0.52 | 0.74 | -0.55 | 1.53 | |
Operating cash flow per share | -0.67 | -0.38 | -0.54 | -0.46 | -0.33 | |
Free cash flow per share | -0.67 | -0.38 | -0.54 | -0.46 | -0.33 | |
Cash per share | 3.03 | 2.65 | 2.11 | 1.64 | 2.83 | |
Book value per share | 2.71 | 2.24 | 1.72 | 1.2 | 2.77 | |
Tangible book value per share | 2.71 | 2.24 | 1.72 | 1.2 | 2.77 | |
Share holders equity per share | 2.71 | 2.24 | 1.72 | 1.2 | 2.77 | |
Interest debt per share | 0.35 | 0.35 | 0.4 | 0.48 | 0.07 | |
Market cap | 40.2M | 28.01M | 31.09M | 44.04M | 41.93M | |
Enterprise value | -77.1M | -72.75M | -44.01M | -9.95M | -80.38M | |
P/E ratio | -0.35 | -0.31 | 0.24 | -0.46 | 0.16 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -1.38 | -1.71 | -1.31 | -2.17 | -2.86 | |
PFCF ratio | -1.37 | -1.7 | -1.31 | -2.17 | -2.86 | |
P/B Ratio | 0.34 | 0.29 | 0.41 | 0.83 | 0.34 | |
PTB ratio | 0.34 | 0.29 | 0.41 | 0.83 | 0.34 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 2.81 | 3.21 | 1.74 | 0.39 | 5.19 | |
EV to operating cash flow | 2.65 | 4.43 | 1.86 | 0.49 | 5.49 | |
EV to free cash flow | 2.64 | 4.41 | 1.85 | 0.49 | 5.49 | |
Earnings yield | -0.7 | -0.82 | 1.05 | -0.55 | 1.61 | |
Free cash flow yield | -0.73 | -0.59 | -0.77 | -0.46 | -0.35 | |
Debt to equity | 0.13 | 0.16 | 0.23 | 0.4 | 0.02 | |
Debt to assets | 0.1 | 0.12 | 0.17 | 0.25 | 0.02 | |
Net debt to EBITDA | 4.28 | 4.45 | 2.97 | 2.14 | 7.9 | |
Current ratio | 11.11 | 7.8 | 8.23 | 6.2 | 11.05 | |
Interest coverage | -97.45 | -207.07 | -134.35 | -101.69 | 137.39 | |
Income quality | 1.04 | 0.71 | 0.95 | 0.81 | -0.22 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.01 | 0.01 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.42 | -0.24 | -0.44 | -0.02 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 6.29 | 5.13 | 5.37 | 3.85 | 9.75 | |
ROIC | -0.21 | -0.2 | 0.35 | -0.32 | 0.53 | |
Return on tangible assets | -0.19 | -0.18 | 0.31 | -0.29 | 0.5 | |
Graham Net | 2.51 | 2.06 | 1.46 | 0.95 | 2.6 | |
Working capital | 129.3M | 110.04M | 87.56M | 60.65M | 117.18M | |
Tangible asset value | 118.34M | 98.09M | 75.37M | 53M | 122.04M | |
Net current asset value | 114.18M | 94.83M | 71.1M | 42.32M | 117.05M | |
Invested capital | 0.13 | 0.16 | 0.23 | 0.4 | 0.02 | |
Average receivables | 2.9M | 2.97M | 1.63M | 269.5K | 270K | |
Average payables | 2.03M | 921K | 1.1M | 487.5K | 831K | |
Average inventory | 5.88M | 6.34M | 3.12M | -692K | 988.5K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.24 | -0.23 | 0.43 | -0.46 | 0.55 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
AVRO Frequently Asked Questions
What is AVROBIO, Inc. stock symbol ?
AVROBIO, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol AVRO
What is AVROBIO, Inc. stock quote today ?
AVROBIO, Inc. stock price is $1.54 today.
Is AVROBIO, Inc. stock public?
Yes, AVROBIO, Inc. is a publicly traded company.